Application of aminothiazole derivative in preparation of medicine for treating diseases caused by high fat diet
By using aminothiazole derivative INNA1605 as MyD88 inhibitor, the inflammation and intestinal flora disorders of obesity and related diseases caused by high-fat diet are solved, and effective treatment of obesity, non-alcoholic fatty liver and type 2 diabetes is achieved. and the recovery of intestinal flora homeostasis.
Patent Information
- Application Number
- CN202411246519.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively regulate obesity and its related diseases caused by high-fat diets, especially in inhibiting inflammation and restoring intestinal flora homeostasis.
The aminothiazole derivative INNA1605 was used as a MyD88 inhibitor. By inhibiting the TIR domain dimerization of the MyD88 protein, the activation of NF-κB was blocked, and the inflammatory response was inhibited, and the diet was adjusted to resist obesity and restore the homeostasis of the intestinal flora.
INNA1605 can not only relieve obesity, non-alcoholic fatty liver and type 2 diabetes, but also restore the intestinal flora. As an inflammatory inhibitor and dietary regulator, it significantly reduces weight and improves liver pathology.
Smart Images

Figure CN118903135A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to the application of an aminothiazole derivative in the preparation of a medicine for treating diseases caused by a high-fat diet. Background Art
[0002] Obesity is a metabolic inflammatory disease, and obesity has become a serious global public health problem. A study published in "Lancet Diabetes Endocrinol" in 2021 stated that the average BMI and overweight / obesity rates have continued to increase among people of all ages in China. Overweight / obesity is a risk factor for cardiovascular disease, type 2 diabetes, and cancer. A large number of prospective studies conducted in the Chinese population have shown that overweight and obesity are associated with an increased risk of multiple diseases, including hypertension, T2DM, and coronary heart disease. Unhealthy lifestyles such as high-fat diets are closely related to the occurrence and development of overweight and obesity. Currently, obesity is mainly alleviated clinically through lifestyle intervention (diet control, exercise), drug therapy, and weight loss surgery. The prevention and treatment of obesity has become an important challenge facing modern society.
[0003] Studies have shown that pathogen-associated molecular patterns (PAMPs) such as LPS bind to the pattern recognition receptor TLR4, activate MyD88 to transmit immune signals through myeloid differentiation protein 88 (MyD88), and initiate an immune response to eliminate the source of the disease. Since almost all Toll-like receptors transmit signals in whole or in part through MyD88, MyD88 has become a key node molecule in the immune response. Most obese patients have long-term intake of high-calorie, high-fat foods, and long-term high-fat diets can lead to intestinal flora disorders, resulting in an increase in the Desulfovibrio flora that produces LPS (lipopolysaccharide), while beneficial flora (Muribaculaceae, Akkermansia) will decrease, which in turn induces impaired intestinal barrier function (Akkermansia can secrete mucin to maintain the intestinal barrier). Harmful substances such as LPS enter the blood, bind to TLR4 on the surface of macrophages in the body, recruit the dimerization of the TIR domain of the MyD88 protein, and then activate NF-kB molecules into the nucleus through a series of cascade reactions, regulate cytokine transcription, and lead to increased expression of IL-1β, TNF-α, and IL-6 inflammatory cytokines, creating an inflammatory microenvironment in the body. More and more studies have shown that obesity and its complications can be alleviated by regulating intestinal flora or the inflammatory environment in the process of obesity through drugs.
[0004] Among the existing clinical treatment methods, adjusting lifestyle such as exercise, controlling diet, and changing dietary structure also plays an important role. Studies have found that by knocking out the MyD88 gene expression in astrocytes in the arcuate nucleus of the hypothalamus (feeding center) of mice, the mice's intake of high-fat diet can be inhibited, but the mice's intake of normal control diet is not inhibited. This shows that by inhibiting the expression of MyD88 in astrocytes in the feeding center area, the intake of high-fat food can be inhibited and the obesity process can be alleviated.
[0005] The prior art provides an aminothiazole derivative INNA1605, whose structure and function are disclosed in the Chinese invention patent CN201110049687.4 "2-aminothiazole derivatives and preparation methods and applications". This type of small molecule compound inhibits the dimerization of the TIR domain of the MyD88 protein, thereby blocking the activation of NF-кB, thereby producing an immunosuppressive effect, and has therapeutic effects in anti-transplant rejection, anti-autoimmune diseases, anti-ischemia reperfusion injury, anti-chronic inflammatory response, anti-endotoxinemia, etc. However, there is no research on the regulatory effect of INNA1605 on diet control and obesity. Summary of the invention
[0006] In order to overcome the shortcomings of the above-mentioned technology, the purpose of the present invention is to provide an aminothiazole derivative for use in the preparation of a drug for treating diseases caused by a high-fat diet. By inhibiting the inflammatory process of obesity and regulating the amount of food to resist obesity and restore the homeostasis of the intestinal flora, the aminothiazole derivative can be used as a dietary regulator, intestinal flora restorer, and inflammation inhibitor for diseases related to a high-fat diet such as obesity, non-alcoholic fatty liver disease, and type 2 diabetes.
[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0008] The present invention provides the use of aminothiazole derivatives in preparing medicines for preventing, alleviating or treating diseases caused by a high-fat diet.
[0009] Preferably, the disease is at least one of obesity, non-alcoholic fatty liver disease and type 2 diabetes.
[0010] Preferably, the pharmaceutical dosage form is a tablet, capsule, oral solution, lozenge, granule, granule, pill, powder, ointment, suspension, powder, solution, injection, suppository, cream, spray, drop or patch.
[0011] The present invention also provides the use of aminothiazole derivatives in preparing inflammation inhibitors.
[0012] Preferably, the aminothiazole derivatives inhibit the expression level of mRNA of inflammatory factors; the inflammatory factors include IL-1β, IL-6, and TNF-α.
[0013] The present invention also provides the use of aminothiazole derivatives in preparing intestinal flora regulating products.
[0014] Preferably, the product is a functional food, a health product or a medicine.
[0015] The present invention also provides the use of aminothiazole derivatives as intestinal flora regulators and inflammation inhibitors in the preparation of drugs for preventing, alleviating or treating obesity, non-alcoholic fatty liver and type 2 diabetes caused by a high-fat diet.
[0016] Preferably, the subject of the aminothiazole derivative is a mouse or a human.
[0017] Preferably, the aminothiazole derivative is 3-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazol-2-yl)propionamide, code-named INNA1605, and the molecular structure is as follows:
[0018]
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The present invention discovered for the first time that the MyD88 inhibitor (INNA1605) can alleviate obesity by controlling the intake of high-fat diets, and also has a certain restorative effect on the homeostasis of intestinal flora. It is not only a targeted inflammatory inhibitor to alleviate obesity, but can also be used as an intestinal homeostasis regulator and dietary regulator to treat obesity. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The daily dietary intake statistics of the four groups were normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40); ns, no significant difference; ****, the difference is statistically significant, p<0.05;
[0022] Figure 2 Weekly body weight records for four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40);
[0023] Figure 3 The abundance of intestinal flora at the Phylum level in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+60mg), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+60mg);
[0024] Figure 4 The abundance of intestinal flora at the Family level in four groups: normal diet + intragastric administration of distilled water (Con), normal diet + intragastric administration of INNA1605 (Con+60mg), high-fat diet + intragastric administration of distilled water (HFD), and high-fat diet + intragastric administration of INNA1605 (HFD+60mg);
[0025] Figure 5 The abundance of intestinal flora at the Genus level in four groups: normal diet + intragastric administration of distilled water (Con), normal diet + intragastric administration of INNA1605 (Con+60mg), high-fat diet + intragastric administration of distilled water (HFD), and high-fat diet + intragastric administration of INNA1605 (HFD+60mg);
[0026] Figure 6 GFAP immunofluorescence in the hypothalamus of mice in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40). Red indicates GFAP positivity.
[0027] Figure 7 The general appearance of mice in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40);
[0028] Figure 8 The gross appearance of the livers of mice in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40);
[0029] Fig. 9 Results of liver pathology HE and Oil Red O staining of mice in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40) (the red color of Oil Red O staining represents lipid droplets);
[0030] Fig.10 The mRNA expression levels of cytokines (IL-6, IL-1β, and TNA-α) in the liver of mice in four groups: normal diet + intragastric administration of distilled water (Con), normal diet + intragastric administration of INNA1605 (Con+40), high-fat diet + intragastric administration of distilled water (HFD), and high-fat diet + intragastric administration of INNA1605 (HFD+40);
[0031] Fig.11 The cytokine content in the liver of mice in four groups: normal diet + intragastric administration of distilled water (Con), normal diet + intragastric administration of INNA1605 (Con+40), high-fat diet + intragastric administration of distilled water (HFD), and high-fat diet + intragastric administration of INNA1605 (HFD+40);
[0032] Fig.12 The results of F4 / 80 immunohistochemistry in the liver of mice in four groups: normal diet + intragastric distilled water (Con), normal diet + intragastric INNA1605 (Con+40), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric INNA1605 (HFD+40) (yellow indicates F4 / 80 positivity);
[0033] Note: Con+40 means normal diet + INNA160540mg / kg mouse / day; Con+60mg means normal diet + INNA160560mg / kg mouse / day; HFD+40 means high-fat diet + INNA160540mg / kg mouse / day; HFD+60mg means high-fat diet + INNA160560mg / kg mouse / day. DETAILED DESCRIPTION
[0034] In order to better explain the present invention, the main contents of the present invention are further explained below in conjunction with specific embodiments, but the contents of the present invention are not limited to the following embodiments.
[0035] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material composition and dosage in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention.
[0036] Example 1: INNA1605 alleviates high-fat diet-induced weight gain
[0037] C57BL / 6J mice were raised in an SPF barrier environment and randomly divided into 4 groups: normal diet + oral administration of distilled water (Con), normal diet + oral administration of INNA160540 mg / kg mouse / day (Con+40), high-fat diet + oral administration of distilled water (HFD), and high-fat diet + oral administration of INNA160540 mg / kg mouse / day (HFD+40). Among them, the high-fat diet group (HFD, HFD+40) began to be given distilled water (control) or INNA160540 mg / kg mouse / day after 4 weeks of high-fat diet, and continued high-fat diet for 12 weeks, during which the food intake was monitored daily and the body weight was recorded at the same time point every week.
[0038] After 16 weeks, mice in different groups were fasted for 12 hours and then anesthetized. Eyeballs were removed to collect blood, and serum was collected by centrifugation. The liver and whole brain of mice were taken and fixed with 4% paraformaldehyde (for subsequent immunofluorescence, immunohistochemistry, HE and other tests) or the tissues were packaged and placed in a liquid nitrogen tank, and then placed in a -80°C refrigerator for use (tissues were taken for subsequent qPCR and inflammatory factor Elisa).
[0039] result:
[0040] The daily diet and weight records of the four groups are as follows: Figure 1 and Figure 2 As shown, the results showed that administration of INNA1605 40 mg / kg mouse / day could inhibit the intake of high-fat diet in mice, but would not inhibit the intake of normal diet.
[0041] The 4 groups of mice were examined for gross examination of the mice and their livers. Figures 7-8 As shown, the results indicate that INNA1605 has a diet-regulated effect and that this dose of INNA1605 can alleviate the weight gain induced by a high-fat diet.
[0042] Example 2: INNA1605 alleviates high-fat diet-induced non-alcoholic fatty liver disease
[0043] The 4 groups of mice in Example 1 were subjected to liver pathology testing. The results are as follows: Fig. 9 As shown, liver steatosis was significantly improved after administration of INNA1605, and there was no toxic effect (i.e., INNA1605 had no pathological damage to the liver of normal mice).
[0044] Example 3: Inflammation-suppressing effect of INNA1605
[0045] The four groups of mice in Example 1 were subjected to GFAP immunofluorescence detection in the hypothalamus region of the mice, liver cytokine (IL-6, IL-1β and TNA-α) mRNA expression level detection, liver cytokine content detection, and liver F4 / 80 immunohistochemistry detection.
[0046] The results of GFAP immunofluorescence detection in the hypothalamus of mice are as follows Figure 6 As shown, high-fat diet-induced astrocyte activation was observed in the ARC region of the hypothalamus of mice, i.e., the GFAP immunofluorescence intensity was enhanced, while administration of INNA1605 significantly reduced the fluorescence intensity of GFAP, which further indicated that INNA1605 had the effect of inhibiting the activation of hypothalamic astrocytes.
[0047] Expression of inflammatory factors and inflammatory cytokines in mouse liver. Fig.10 and 11 As shown, INNA1605 can reduce the expression of liver inflammatory factors (IL-6, IL-1β and TNA-α) and improve the inflammatory microenvironment. At the same time, qPCR results showed that INNA1605 can significantly reduce the mRNA levels of liver inflammatory factors (IL-6, IL-1β and TNA-α).
[0048] F4 / 80 is a surface marker of mouse liver macrophages, indicating the infiltration of liver macrophages (inflammatory cells). The results of liver F4 / 80 immunohistochemical detection are as follows: Fig.12 As shown, after administration of INNA1605, the F4 / 80-positive area in the liver was significantly reduced, confirming the anti-inflammatory effect of INNA1605.
[0049] Example 4: Intestinal flora regulation effect of INNA1605
[0050] C57BL / 6J mice were raised in an SPF barrier environment and randomly divided into 4 groups: normal diet + intragastric distilled water (Con), normal diet + intragastric distilled water (60 mg INNA1605 / kg mouse / day) (Con+60), high-fat diet + intragastric distilled water (HFD), and high-fat diet + intragastric distilled water (60 mg INNA1605 / kg mouse / day) (HFD+40). After 4 weeks of high-fat diet, distilled water (control) or 60 mg INNA1605 / kg mouse / day was given, and the high-fat diet was continued for 12 weeks. At the end of the period, the mice were killed by dislocation of the neck. Pay attention to aseptic operation, and collect the contents of the cecum and colon of the mice by laparotomy. The contents were collected into sterile EP tubes after high temperature and high pressure, and then quickly frozen by liquid nitrogen and transferred to a -80℃ refrigerator for use (subsequent dry ice delivery for inspection), or directly transported to the testing agency on dry ice for 16S RNA detection.
[0051] like Figure 3As shown, the results showed that a high-fat diet could induce intestinal flora disorders in mice, among which the Phylum level was visible, and the Firmicues / Bacteroidota ratio was restored after treatment with INNA1605. The intestinal flora disorders such as Desulfobacterota, Deferribacterota, and Verrucomicrobiota caused by a high-fat diet could also be improved after treatment with INNA1605.
[0052] like Figure 4 As shown in the figure, at the Family level, it can be seen that the number of bacteria that increased significantly after high-fat diet induction, such as Desulfovibrionaceae (harmful bacteria that can produce LPS) and Deferribacteraceae (harmful bacteria), was significantly downregulated after treatment with INNA1605, and the number of bacteria that was significantly downregulated after high-fat diet induction, such as Muribaculaceae (beneficial bacteria - belonging to the Bacteroidetes, decomposing complex polysaccharides in food and producing SCFAs, such as propionic acid, butyric acid, acetic acid, etc.), Akkermansiaceae (beneficial bacteria), Rikenellaceae (beneficial bacteria), Clostridia_UCG-014 (beneficial bacteria that can consume succinic acid), was significantly restored after treatment with INNA1605.
[0053] like Figure 5 As shown in the figure, at the genus level, the abundance of Mucispirillum, Desulfovibrio, Romboutsia, Faecalibaculum, and Acetatifactor induced by a high-fat diet can be downregulated after INNA1605 treatment, while the Muribaculaceae and Akkermansia induced by a high-fat diet can be restored. This shows that INNA1605 has the effect of restoring the homeostasis of intestinal flora and can be used as an intestinal flora restoration agent.
[0054] The present invention can prove that INNA1605 reduces body weight by inhibiting high-fat diet food intake by daily monitoring of the food intake of mice under normal diet and high-fat diet (i.e., gavage) and weekly monitoring of body weight changes.
[0055] By collecting the feces of mice in four groups, including normal diet + oral gavage of distilled water, normal diet + oral gavage of INNA1605, high-fat diet + oral gavage of distilled water, and high-fat diet + oral gavage of INNA1605, and using 16S RNA sequencing technology, the changes in intestinal flora of mice in each group were evaluated, confirming that the homeostasis of intestinal flora was restored after oral gavage of INNA1605.
[0056] The expression changes of astrocyte marker (GFAP) in the ARC region of the hypothalamus of the four groups of mice were detected by immunofluorescence technology to evaluate the changes in astrocyte proliferation in the ARC region of the hypothalamus, and then it was proved that the ARC region of the hypothalamus of mice was improved after oral gavage of INNA1605.
[0057] Obesity-related changes in the four groups of mice were detected by pathology (HE, Oil Red O), cytokine (IL-1β, TNF-α, IL-6) Elisa, immunohistochemistry, qPCR and other techniques, and were alleviated after oral gavage with INNA1605.
[0058] The innovation of the present invention lies in the discovery that the MyD88 inhibitor (INNA1605) can alleviate obesity by controlling the intake of high-fat diets, and at the same time has a certain restorative effect on the homeostasis of intestinal flora. It is not only a targeted inflammatory inhibitor to alleviate obesity, but can also be used as an intestinal homeostasis regulator and dietary regulator to treat obesity.
[0059] The above-described embodiments only express the implementation methods of the present invention, but cannot be understood as limiting the scope of the invention patent. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.
Claims
1. The use of aminothiazole derivatives in the preparation of drugs for preventing, alleviating or treating diseases caused by a high-fat diet.
2. The use according to claim 1, characterized in that: The disease is at least one of obesity, non-alcoholic fatty liver disease, and type 2 diabetes.
3. The use according to claim 1, characterized in that: The drug dosage form is tablet, capsule, oral liquid, lozenge, granule, granule, pill, powder, ointment, suspension, powder, solution, injection, suppository, cream, spray, drop or patch.
4. Application of aminothiazole derivatives in the preparation of inflammation inhibitors.
5. The use according to claim 4, characterized in that: The aminothiazole derivatives inhibit the expression level of mRNA of inflammatory factors; the inflammatory factors include IL-1β, IL-6, and TNF-α.
6. Application of aminothiazole derivatives in the preparation of intestinal flora regulating products.
7. The use according to claim 6, characterized in that: The product is a functional food, a health product or a medicine.
8. Use of aminothiazole derivatives as intestinal flora regulators and inflammation inhibitors in the preparation of drugs for preventing, alleviating or treating obesity, non-alcoholic fatty liver disease and type 2 diabetes caused by a high-fat diet.
9. The use according to claim 8, characterized in that: The subject of the aminothiazole derivative is a mouse or a human.
10. The use according to claim 1 or 4 or 6 or 8, characterized in that: The aminothiazole derivative is 3-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazol-2-yl)propionamide, code-named INNA1605, and has the following molecular structure:
